e-learning
resources
Paris 2018
Sunday, 16.09.2018
Role of IgE and interleukin (IL)-5 in Th2-cell signatures
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Is omalizumab response influenced by passive smoking in severe asthma?
D. Cavalet Blanco (Porto Alegre, Brazil), L. Martins Becher (Porto Alegre, Brazil), L. Zani Da Silva (Porto Alegre, Brazil), C. Rocha Dullius (Porto Alegre, Brazil), F. Kahan (Porto Alegre, Brazil), S. Rocha Machado (Porto Alegre, Brazil), J. Miguel Chatkin (Porto Alegre, Brazil)
Source:
International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures
Session:
Role of IgE and interleukin (IL)-5 in Th2-cell signatures
Session type:
Thematic Poster
Number:
1129
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Cavalet Blanco (Porto Alegre, Brazil), L. Martins Becher (Porto Alegre, Brazil), L. Zani Da Silva (Porto Alegre, Brazil), C. Rocha Dullius (Porto Alegre, Brazil), F. Kahan (Porto Alegre, Brazil), S. Rocha Machado (Porto Alegre, Brazil), J. Miguel Chatkin (Porto Alegre, Brazil). Is omalizumab response influenced by passive smoking in severe asthma?. 1129
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
The influence of smoking on the treatment response in patients with asthma
Source: Annual Congress 2007 - PG15 - Difficult-to-treat asthma: dealing with smoker patients
Year: 2007
The effect of passive smoking on severity of children asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 453s
Year: 2001
Are severe asthmatics still smoking?
Source: International Congress 2017 – Smoking and health hazards
Year: 2017
Omalizumab (Xolair®) reduces exacerbations in patients with moderate-to-severe persistent allergic asthma independent of former smoking status
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008
Are a degree of asthma therapy related to asthma control impairment?
Source: Eur Respir J 2003; 22: Suppl. 45, 370s
Year: 2003
Omalizumab is effective in patients with severe persistent allergic asthma in a real-life setting irrespective of age
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
The value of behavioral regulation in patients with bronchial asthma in case of smoking cessation
Source: International Congress 2019 – From tobacco-related comorbidities to tobacco cessation
Year: 2019
Passive smoking and the airways reaction to inhaled corticosteroid therapy in children with asthma
Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma
Year: 2008
Does FENO predict FEV
1
response to exposure cessation in occupational asthma?
Source: Annual Congress 2012 - Occupational asthma
Year: 2012
Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline
Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges
Year: 2009
Passive smoking, asthma and asthma severity in the EGEA study
Source: Eur Respir J 2001; 18: Suppl. 33, 373s
Year: 2001
Returning asthma symptoms correlate with free IgE upon omalizumab cessation
Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities
Year: 2007
Impact of prior smoking exposure and COPD comorbidity on treatment response to monoclonal antibodies in patients with severe asthma
Source: ERJ Open Res, 7 (3) 00190-2021; 10.1183/23120541.00190-2021
Year: 2021
Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study
Source: International Congress 2017 – Monitoring asthma control
Year: 2017
An increase in bronchial responsiveness is associated with continuing or restarting smoking
Source: Annual Congress 2005 - Highlights of asthma epidemiology
Year: 2005
What influences the response to training of inhalation technique in patients with asthma and COPD?
Source: International Congress 2018 – Pulmonary drug delivery: inhaler use, devices and technologies
Year: 2018
Which are the factors and causes that lead to omalizumab withdrawal in severe asthma patients?
Source: International Congress 2018 – New developments in the treatment of asthma
Year: 2018
The airways response to inhaled corticosteroid therapy in children with asthma exposed to environmental tobacco smoke
Source: Annual Congress 2013 –Passive smoking, children and students (young adults)
Year: 2013
Greater risk of incident asthma cases in adults with allergic rhinitis: importance of cigarette smoking
Source: Annual Congress 2006 - New investigational approaches to smoking and smoking cessation
Year: 2006
Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV
1
in patients with severe persistent allergic asthma irrespective of age
Source: Eur Respir J 2005; 26: Suppl. 49, 48s
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept